These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 6360514)

  • 1. Rheumatoid arthritis: disease-modifying antirheumatic drugs.
    Kirwan JR; Currey HL
    Clin Rheum Dis; 1983 Dec; 9(3):581-99. PubMed ID: 6360514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration.
    Anderson JJ; Wells G; Verhoeven AC; Felson DT
    Arthritis Rheum; 2000 Jan; 43(1):22-9. PubMed ID: 10643696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current concepts in clinical therapeutics: disease-modifying drugs for rheumatoid arthritis.
    Pugh MC; Pugh CB
    Clin Pharm; 1987 Jun; 6(6):475-91. PubMed ID: 3319362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The limits of controlled clinical studies: the case of rheumatology].
    Portioli I
    Ann Ital Med Int; 2000; 15(1):39-46. PubMed ID: 10842890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Long term treatment of rheumatoid arthritis. Experiences with D-penicillamine in comparison with gold and immunosuppressive drugs (author's transl)].
    Warnatz H; Scheiffarth F; Gutmann W
    Med Klin; 1975 Sep; 70(38):1509-15. PubMed ID: 810648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
    Rau R; Schleusser B; Herborn G; Karger T
    J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity.
    Stone M; Fortin PR; Pacheco-Tena C; Inman RD
    J Rheumatol; 2003 Oct; 30(10):2112-22. PubMed ID: 14528503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined disease-modifying chemotherapy for intractable rheumatoid arthritis.
    Bitter T
    Clin Rheum Dis; 1984 Aug; 10(2):417-28. PubMed ID: 6391796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
    Sesin CA; Bingham CO
    Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease-modifying antirheumatic drugs, including methotrexate, gold, sulfasalazine, antimalarials, and D-penicillamine.
    Conaghan PG; Brooks P
    Curr Opin Rheumatol; 1996 May; 8(3):176-82. PubMed ID: 8796975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical studies with salazopyrine--consequences and perspectives].
    Zeidler H
    Z Rheumatol; 1987; 46(2):59-66. PubMed ID: 2885985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.
    Ogrendik M
    Clin Ther; 2009 Aug; 31(8):1754-64. PubMed ID: 19808134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Follow-up study of patients with rheumatoid arthritis over a period of more than 10 years (1966-1978): analysis of disease progression and treatment in 100 cases (author's transl)].
    Amor B; Herson D; Cherot A; Delbarre F
    Ann Med Interne (Paris); 1981; 132(3):168-73. PubMed ID: 7294583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.
    Hurst S; Kallan MJ; Wolfe FJ; Fries JF; Albert DA
    J Rheumatol; 2002 Aug; 29(8):1639-45. PubMed ID: 12180722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response.
    American College of Rheumatology Committee to Reevaluate Improvement Criteria
    Arthritis Rheum; 2007 Mar; 57(2):193-202. PubMed ID: 17330293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
    Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study.
    Anderson JJ; Bolognese JA; Felson DT
    Arthritis Rheum; 2003 Nov; 48(11):3031-8. PubMed ID: 14613263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with stable long-standing rheumatoid arthritis continue to deteriorate despite intensified treatment with traditional disease modifying anti-rheumatic drugs--results of the British Rheumatoid Outcome Study Group randomized controlled clinical trial.
    Symmons D; Tricker K; Harrison M; Roberts C; Davis M; Dawes P; Hassell A; Knight S; Mulherin D; Scott DL;
    Rheumatology (Oxford); 2006 May; 45(5):558-65. PubMed ID: 16263778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or american college of rheumatology criteria for remission.
    Sokka T; Pincus T
    J Rheumatol; 2003 Jun; 30(6):1138-46. PubMed ID: 12784382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.